NGMC Medical Staff Podcast, Episode 13: Pulmonology

Claim CME Credit https://www.surveymonkey.com/r/W88KJD3 Speakers Hosted by Larry Dudas, MD and Dan Robinson, MD Vijaya Ramalingam, MD, FCCP Pulmonary and Critical Care Physician, NGPG Program Director, Pulmonary and Critical Care Medicine Fellowship, NGMC Stefanie Kananda, DO Northeast Georgia Physicians Group Pulmonology Disclosures None Learning Objectives 2026 GOLD report: Focus on revision New FDA approved medication - Ensifentrine, ENHANCE 1 and 2 trials New therapeutic targets: Biologics - BOREAS, NOTUS and MATINEE trials Expiration Date 6/1/28 Accreditation Statement The Northeast Georgia Medical Center & Health System, Inc. is accredited by the Medical Association of Georgia to provide continuing medical education for physicians. The Northeast Georgia Medical Center & Health System, Inc. designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. If you have technical difficulties or questions contact [email protected]. Articles referenced in today's podcast Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304 Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025;236:107846. doi:10.1016/j.rmed.2024.107846 Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025;392(17):1710-1720. doi:10.1056/NEJMoa2413181